There are several ways in which the COVID-19 pandemic may affect the prevention and
management of thrombotic and thromboembolic disease, either direct effect or the indirect
effects of infection, such as through severe illness and hypoxia, may predispose patients to
thrombotic events. The severe inflammatory response, critical illness, and underlying
traditional risk factors may all predispose to thrombotic events. Therefore, considering the
high-risk profile of cardiovascular comorbidities in patients with COVID-19, it is
scientifically relevant to evaluate the use of anticoagulants as an adjunctive treatment in
the context of COVID-19. Indeed, it will be tested the hypothesis that the use of moderate
dose of rivaroxaban has a beneficial effect in the treatment of patients with a confirmed or
probable diagnosis of COVID-19 infection, with no clear indication for hospitalization (mild
and moderate cases) upon initial medical care, by reducing the need of hospitalization due to
complications related to COVID-19.
Phase:
Phase 4
Details
Lead Sponsor:
Hospital Alemão Oswaldo Cruz
Collaborators:
Bayer Brazilian Clinical Research Institute Brazilian Research In Intensive Care Network Hospital do Coracao Hospital Israelita Albert Einstein Hospital Moinhos de Vento Hospital Sirio-Libanes